Journal Basic Info
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.Major Scope
- Palliative Care
- Ovarian Cancer
- Hormone Therapy
- Kidney Cancer
- Paediatric Cancers
- Lymphoma
- Gastrointestinal Cancer
- Sarcomas
Abstract
Citation: Clin Oncol. 2016;1(1):1149.DOI: 10.25107/2474-1663.1149
Orbital Myositis Secondary to Cytotoxic T-LymphocyteAssociated Protein 4 Antibody – A Case Report
Patel D, Tremont A and Fuloria J
epartment of Oncology, Ochnser Health System, USA
PDF Full Text Case Report | Open Access
Abstract:
Ipilimumab, a monoclonal antibody targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) was approved in 2011 for the treatment of metastatic melanoma after a phase 3 study showed an improvement in overall survival. The majority of adverse events related to the drug noted in the study were immune-mediated, causing dermatologic, gastrointestinal and endocrine dysfunction. These side-effects are consistent with the idea that by enhancing a patient’s immunoreactivity there will be increased self reactivity. This report describes a patient with orbital myositis secondary to Ipilimumab.
Keywords:
Cite the Article:
Patel D, Tremont A, Fuloria J. Orbital Myositis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Antibody – A Case Report. Clin Oncol. 2016; 1: 1149.
